The United States Patent and Trademark Office (USPTO) has granted patent US12583907B2, titled 'Modified plasma clotting factor VIII and method of use thereof,' to AAVnerGene, INC. The patent covers modified human factor VIII polypeptides that exhibit enhanced factor VIII activity, specifically detailing amino acid substitutions at various positions. It also includes viral vectors encoding these polypeptides and their application in treating FVIII deficiencies, such as hemophilia A.

This patent grant is primarily relevant to pharmaceutical and biotechnology companies involved in the research, development, and commercialization of gene therapies or protein-based treatments for hemophilia A. While it does not impose direct compliance obligations on other entities, it signifies intellectual property protection for specific therapeutic innovations in this area. Companies operating in this space should be aware of this patent and its claims to ensure freedom to operate and to inform their own R&D strategies.